Article

Clinical activity of MAPK targeted therapies in patients with non-V600 BRAF mutant tumors

2022-02-21

Abstract excerpt

<h4>Purpose</h4> Non-V600 mutations comprise approximately 35% of all BRAF mutations in cancer. Many of these mutations have been identified as oncogenic drivers in a wide array of cancer types and can be classified into three Classes according to molecular characteristics. Consensus treatment strategies for Class 2 and 3 BRAF mutations have not yet been established. <h4>Methods</h4> We performed a systematic revi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d32116e8-5590-5568-9a76-b2255a080ff7
DOI: 10.1101/2022.02.17.22271120

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Clinical activity of MAPK targeted therapies in patients with non-V600 BRAF mutant tumorsDOI 10.1101/2022.02.17.22271120Read

Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant TumorsSemantic proximity Read

Clinical activity of Mitogen-Activated Protein Kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancersSemantic proximity Read

CDK4/6 and SHP2 mediate BRAF/MEK inhibitor resistance in Class 2 and 3 BRAF mutant cancersSemantic proximity Read

Clinical Activity of Mitogen-Activated Protein Kinase Inhibitors in Patients With MAP2K1 (MEK1)-Mutated Metastatic Cancers.Semantic proximity Read

Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLCSemantic proximity Read

The clinical, genomic, and transcriptomic landscape of BRAF mutant cancersSemantic proximity Read

BRAF-targeted therapy in non-melanomatous BRAF-mutant tumours: a systematic review of broad but histology-modulated efficacy.Semantic proximity Read

Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort.Semantic proximity Read

[Expert consensus on BRAF inhibitors in the treatment of malignant solid tumors (2024 edition)].Semantic proximity Read

Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature.Semantic proximity Read

Defining and Targeting BRAF Mutations in Solid Tumors.Semantic proximity Read

Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database.Semantic proximity Read